Hematology (Amsterdam, Netherlands) · 2026
In-hospital and short-term outcomes in patients with atrial fibrillation undergoing chimeric antigen receptor-T cell therapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao Nan, Li Wen, Chen Qian, Zhang Qi, Yu Qiuyan, Liu Na, Zhu Xunxun, Yin Zixun, Wang Hui, Zhang Kui, Zhou Chi, Fang Min, Dong Hongjing
Аннотация
BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) therapy is an innovative immunotherapy for hematologic malignancies. Cardiovascular complications associated with CAR-T therapy have also received increasing attention. However, the impact of atrial fibrillation (AF) on outcomes in patients undergoing CAR-T therapy remains poorly understood.
METHODS: We conducted a retrospective study using the National Readmission Database (NRD) to identify adult patients who underwent CAR-T therapy between 2017 and 2020. We divided the patients into two groups based on the presence of AF to study in-hospital and 30-day outcomes. Propensity score matching was performed, and outcomes were analyzed using multivariable logistic regression and Cox proportional hazards models. The primary outcomes included in-hospital mortality, stroke, sepsis, and 30-day readmission.
RESULTS: A total of 3,003 hospitalizations were identified, incluing 162 (5.39%) patients with AF. Patients in the AF group were older and more likely to be male. Compared with patients without AF, those with AF had higher rates of in-hospital mortality (7.4% vs 3.2%; P = 0.007), sepsis (18.5% vs 8.8%; P < 0.001), and stroke (8.0% vs 3.2%; P < 0.001). No significant differences were observed in neurotoxicity or acute kidney injury. In 30-day readmissions, there were no differences in all-cause readmission or in readmissions due to cancer- or treatment-related events, sepsis or infection, and neurologic events.
CONCLUSION: Among patients undergoing CAR-T cell therapy, AF was associated with a higher risk of in-hospital mortality, stroke and sepsis. However, the 30-day all-cause readmission rate showed no difference between the AF group and the non-AF group.
METHODS: We conducted a retrospective study using the National Readmission Database (NRD) to identify adult patients who underwent CAR-T therapy between 2017 and 2020. We divided the patients into two groups based on the presence of AF to study in-hospital and 30-day outcomes. Propensity score matching was performed, and outcomes were analyzed using multivariable logistic regression and Cox proportional hazards models. The primary outcomes included in-hospital mortality, stroke, sepsis, and 30-day readmission.
RESULTS: A total of 3,003 hospitalizations were identified, incluing 162 (5.39%) patients with AF. Patients in the AF group were older and more likely to be male. Compared with patients without AF, those with AF had higher rates of in-hospital mortality (7.4% vs 3.2%; P = 0.007), sepsis (18.5% vs 8.8%; P < 0.001), and stroke (8.0% vs 3.2%; P < 0.001). No significant differences were observed in neurotoxicity or acute kidney injury. In 30-day readmissions, there were no differences in all-cause readmission or in readmissions due to cancer- or treatment-related events, sepsis or infection, and neurologic events.
CONCLUSION: Among patients undergoing CAR-T cell therapy, AF was associated with a higher risk of in-hospital mortality, stroke and sepsis. However, the 30-day all-cause readmission rate showed no difference between the AF group and the non-AF group.